PPW
NBIX icon

Parcion Private Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Parcion Private Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$512K Buy
3,883
+107
+3% +$14.2K 0.03% 226
2025
Q4 		$536K Buy
3,776
+1,344
+55% +$195K 0.03% 222
2025
Q3 		$341K Buy
+2,432
New +$330K 0.02% 255

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parcion Private Wealth's NBIX Position: Q1 2026 in Review

Parcion Private Wealth increased its Neurocrine Biosciences (NBIX) stake by 2.8% in Q1 2026, buying an estimated $14.2K and bringing the position to 3,883 shares worth $512K. The position accounts for 0.03% of the portfolio, ranked #226.

Parcion Private Wealth first reported a position in NBIX in Q3 2025 and has held it in 3 quarters since. The position peaked at $536K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Parcion Private Wealth held 3,883 shares of Neurocrine Biosciences worth $512K as of Q1 2026.
  • Parcion Private Wealth bought 107 Neurocrine Biosciences shares in Q1 2026, an estimated $14.2K.
  • Neurocrine Biosciences made up 0.03% of Parcion Private Wealth's portfolio in Q1 2026, its #226 holding.
  • Parcion Private Wealth first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Parcion Private Wealth's Neurocrine Biosciences position peaked at $536K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Parcion Private Wealth's 13F filing for Q1 2026, filed 22 Apr 2026.